



ENERKON SOLAR AND NEW TECHNOLOGIES DIVISION (ENKS - OTC BB)

CORPORATE PROFILE FOR INVESTOR RELATIONS

Enerkon Solar International Inc. (ENKS OTC PINK) General Corporate Profile for Investor Relations and Shareholder use as an educational guide, on the Composition and Operations, Forward Looking Statements and Business Goals of the Company.

Very Important: Read all legal disclaimers and statements regarding the contents of this Corporate Overview which is not an offer to buy or sell shares and all statements and representations may change at any time both positive or negative and should not be relied upon for business or investment decisions, only official filings with the SEC or other regulatory bodies should be reviewed to gain specific information and by an expert who is sophisticated in the industry and business. Statements are forward looking and/or for educational purposes only and not to be relied upon for investment or business decisions regarding Enerkon Solar International Inc. .

ENERKON SOLAR AND NEW TECHNOLOGIES DIVISION (ENKS - OTC BB) PINK)

CORPORATE PROFILE FOR INVESTOR RELATIONS

Enerkon Solar International Inc., Initially established in September 2016, aspires to be a leader in Utility Scale PV Power Plants and renewable systems, with a particular focus on the Middle East and Africa, who have the greatest urgent need, the highest Solar Intensity Coverage compared to other parts of the world, the best ROI, compared to other geographic regions and less resistance to entry into the major markets.

In the last year, we have achieved in addition to our Projects completed through Global Star Holdings – HK, we have been awarded (September 2017) a 500 MW \$600 Million USD Utility Scale PV Plant in Gaza Province – Mozambique, currently in the last phases of documentation for entry of our funding syndicate.

This at 0.13 cents kWh and in addition Enerkon Solar International Inc. has further been awarded an additional two (2) more 500MW Utility Scale PV Solar Plants to be built this year in the provinces of Cabo Delgado and Nampula.

These are long term participation in PPA via BOOT structures with the Government of Mozambique, who are the sole guarantor over 30 years.

Our Long Term Strategic Plan, Vision 2028 is a long-term road-map to achieve our growth objectives and our technology and cost leadership goals. In executing our Long Term Strategic Plan, we are focusing on providing utility-scale PV solar energy solutions using our modules to key geographic markets that we believe have a compelling need for mass-scale PV electricity, including markets throughout the Americas, Asia, the Middle East, and Africa.

As part of our Long Term Strategic Plan, we are focusing on opportunities in which our PV solar energy solutions can compete directly with fossil fuel offerings on an LCOE or similar basis, or complement such fossil fuel electricity offerings. Execution of the Long Term Strategic Plan entails a prioritization of market opportunities worldwide, relative to our core strengths and a corresponding allocation of resources around the globe.

This prioritization involves a focus on our core utility-scale offerings and in the U.S. While it is unclear how rooftop and distributed generation solar, might impact our core utility-scale offerings in the next several years, we believe that utility-scale solar, will continue to be a compelling solar offering for companies with technology and cost leadership and will continue to represent an increasing portion of the overall electricity generation mix.

Acquisition of strategic companies in the Panel and Technology Sectors as well as other small and mid- level renewable energy companies is also a large part of our near term plans.

COMPANY OVERVIEW

ENKS SECURITY DETAILS

Share Structure

Market Cap

10,471,004

02/16/2020

Authorized Shares

200,000,000

09/30/2019

Outstanding Shares

65,177,510

10/30/2019

Float

15,000,000

09/30/2019

Par Value

0.002

Transfer Agent
Standard Registrar
and Transfer Co., Inc.

CONTACT DETAILS

13620 Weyburn Drive
Delray Beach, FL 33446

Tel. +1(561) 431-7762

www.enerkoninternational.com

info@enerkoninternational.com

Recent Events:

In early 2019 the company established a new technology division with the purpose of seeking out and purchasing new disruptive technology in the AI, IT, Nanotech, Geotech, Argi-tech, new battery disruptive technology, renewable energy, defense, fintech and new apps development by SMEs as well as other sectors with the potential to increase shareholder value.

ENKS is now the owner of New Disruptive Fuel Cell technology that is patented in the Name of ENKS and is slated for release into commerce in late 2020 or early 2021 – the Market Value of this new Patent exceeds \$500 Million USD while the valuation may not be correct or could lose all of its value in case of negative market risk factors;

ENKS has purchased 20% of ALBAYRAKLAR Defense Company in Turkey with plans to purchase a total of 51% whereas all of the Patents and patented new defense and police equipment technology and IP Rights are currently owned in the amount of 51% through the creation of a wholly owned corporate division of ENKS, created and called Wattozz (Stingray in Turkish) Holdings Inc. – this transaction was valued by BakerTilly and has a 1.1 Billion USD Valuation (we do not state the valuation is correct or that it may hold its value and may lose all of its value in case of negative market conditions) ;

ENKS has further plans to expand its core EPC Solar PV plant construction, investment and implementation in East Africa after maintaining 3 major projects one of which is currently running towards completion in 18-20 months more in Mozambique (Negative market forces may effect these plans and little or no growth could transpire or even possible a total loss of investment in case of negative market forces) .

ENKS has acquired the Patent and Trademark for revolutionary Passive Immunity Drug COVID-SHIELD PI™ and is in the last stages to initiate Human Trials this year and global Marketing before Q4 2020 using aggressive lobby for regulatory waivers, exemptions and approvals where possible*

CEO BIO

Benjamin Ballout, currently serves on numerous multinational corporations board including serving as a Managing Director of Diplomatic Trade Ltd., a Multinational corporation represents government in Trade, Liaisons, and Lobbying with an Executive experience bringing in over Twenty years of experience in various industries from Finance, Real Estate Development, Aerospace and Defense, and International Affairs with an understanding of the international trade and policies that affect global outcomes is part of his work functions.

Benjamin is also involved in numerous Nation Buildings projects along with multiple Humanitarian relief effort. He had the privilege to be among forward thinkers to participate in the project on U.S. National Security Reform Act.

Benjamin role at Diplomatic Trade is acting as an Advisor to high-level stakeholders/ministers on policy and procedures that could impact the organizations international reputation using his Extensive experience in governance and strategy of multilateral institutions, alongside, he Promote implementation of strategies through a range of tactics, to influence and shape thinking to ensure progress in climate and renewable energy-related forums.

Benjamin also sits on the boards of:

- Diplomatic Trade Ltd.
- Rothschild & Lewis LLC
- Thomas H. Miner & Associates
- The Arab African Council on Socio-Economic Development

**CFO and Senior Vice President of International Business Development
Dr. Ibrahim Mosaad El Nattar (Egyptian Citizen)**

Dr. Ibrahim EL Nattar, a former Scientific Adviser to the Embassy of The Arab Republic of Egypt in Maputo, Mozambique (1999-2006) and having a 30 year career in Government and International Affairs focused on Scientific, Energy, Social Development, Security and Development Finance was chosen for the position of SVP Intl. Business Development Dr. El Nattar is well known throughout the Arab and African Region and is a key member of our business development team as well as our financial oversight and development group within the company.

Some of the international institutions Dr. EL Nattar has worked with or is currently working with are:

- Arab Bank for Economic Development in Africa (BADEA).
- African Development Bank (ADB). African Development Fund (ADF).
- Islamic Bank. AGA Khan Foundation. Canadian International Development Agency (CIDA).
- The New Partnership for Africa's Development (NEPAD) (Comprehensive Africa Agriculture Development Program (AADP)
- Food and Agriculture Organization (FAO). World Health Organization (WHO).
- United Nations Development Program (UNDP).
- World Association of Women Entrepreneurs
- The Chartered Institute of Logistics and Transport CILT
- Dr. Ibrahim El Nattar also Serves as a founding associate member of the Inter-Governmental Renewable Energy Association (AREC) founded by Prince and Princess Asem Sanaa Bin Nayef (Kingdom of Jordan) in his capacity as Deputy Secretary General of the Arab African Council on Socioeconomic Development (AACSED, a UK Registered NPO) the AREC is an associate member of the Arab League ECOSC in Cairo, Egypt.

Dr. Ibrahim El Nattar sits on Numerous Boards of public and private organizations and is active in consultation on policy recommendations to Government and Private sector in relation to Renewable Energy, Security and Socioeconomic Development.

Corporate Contact:

Enerkon Solar International Inc
13620 Weyburn Drive
Delray Beach, Florida 33446
Tel. 1+5614317762
Email: info@enerkoninternational.com
WEB: <https://www.enerkoninternational.com>

Management Discussion and Analysis

ENKS New Technology Division recent acquisitions of Intellectual Property Rights, Patents, Trade Marks and other Products – An Overview of Potential Market Value

"ENKS Core business model is supporting EPC contract acquisition, implementation and investment, in utility scale solar PV utility plants in Africa and other regions internationally":

ENKS was originally established in 2016, as a private corporation and partnership, completing EPC contracts related to the implementation and delivery to customers, Turn Key utility scale PV, power plants in Turkey and East Africa, as well as other potential locations.

During the end of 2017 and the beginning of 2018, the company decided to change their core EPC contract partners and shareholders, as well as modifying the corporate structure to become a publicly listed company on the US OTC pink market exchange system, under the symbol ENKS for its trading shares.

After this historic event for the company, additional solar projects were awarded in Mozambique, the first of which in Gaza province has been running since late 2017 until today's date with excellent success, under a cost plus 10% structure, this having a power output profile of 500 megawatts and a 25 years Power Purchase Agreement with the government responsible utility in Mozambique, upon completion and delivery to the national grid, ENKS will enjoy the benefits of its participation in the cost plus 10% EPC contract continuously underway and whereas currently, revenues are listed as deferred, while cash flow and other said components such as inventories, and related items are listed in accordance with GAAP and industry standards for the renewable energy markets customarily.

The project completion date is expected to be 18 to 20 months from today's date respectively due to several delays caused by controversies between the World Bank and the government of Mozambique, and now the COVID-19 global pandemic, which has affected logistics and delivery dates.

ENKS in addition to the foregoing core renewable energy business and ongoing project completion operation in Mozambique, the company also acquired exclusive rights to build finance and deliver a similar scale PV power plant with a 500 megawatts output profile, similar to the current project in Gaza province.

This new, direct award, is located in the province of Cabo Delgado, and in addition to this project, yet a further expansion of the renewable energy grid project in the country, ENKS adds another EPC – BOOT, solar PV power plant for the state of Nampula as well, this also being an output ratio of 500 megawatts.

All of the foregoing projects and transactions are self-financed, without using capital market funds or shareholders' funds, and are organized through third party's financial support, which the company has enjoyed over the past several years until the current day, whereby all of the company's project have been fully supported financially, without unduly encumbrance upon shareholders, or creating delusion or other capital market access issues, which many companies are burden with.

Once delivery of the first EPC contract is made, then the second project at Cabo Delgado will be activated in a timely manner due to the fact that preliminary feasibility studies have already been accomplished over the previous months, leading up to today's date, and this will streamline our entry into that extended market considerably.

OTHER NEW DISRUPTIVE TECHNOLOGY ACQUIRED BY ENKS

THE ENKS HAS ACQUIRED A PATENT FOR NEW DISRUPTIVE TECHNOLOGY in THE FORM OF AN ALUMINUM AIR FUEL CELL BATTERY, A REVOLUTIONARY CONCEPT FOR LONG-RANGE ELECTRIC VEHICLE POWER, WEIGHT AND COST REDUCTION METRICS:

- **The ENKS Aluminum Air Fuel Cell Battery Technology Patent**, owed by the company, has completed its initial proof of concept and marketing partnership syndication, as well as other important features required for the launch into the commercial arena, using this revolutionary new technology which produces a 38% less weight battery, than the commonly used lithium or cobalt batteries technologies on the market, and with an extended range of more than 60% as to range to charge ratio, and in addition, the cost per kilometer is at or well below the national standards in most countries for electric vehicle power cost basis and cost load calculations.
- The primary value of this new patented technology, lays in the fact that manufacturers will save over 38% per unit cost, by using this new fuel cell battery technology as opposed to current lithium ion/cobalt or other technologies currently in use today, and in addition the Aluminum Air fuel cell battery owned by ENKS its virtually non toxic and will not explode or cause fire damage, as opposed to other battery technologies currently in use (lithium ion/cobalt/others).
- In addition to the foregoing cost savings and utility for safety and distance range costs and other variables, the Aluminum Air fuel cell battery technology does not require recharge, and its in fact a plug and play battery, which can be exchanged within a few minutes at participating national franchises, gas stations or maintenance shops across the host country, whereby once the fuel cell has sufficiently discharged, but before it completely discharges, the driver will simply pull into an exchange station and swap out the discharged fuel cell battery, for a new fully charged cell, on inventory across the country franchise participants facilities, as the case may be. In addition, a rapid, high quality, and high security, cost and payment system has been established, using a odometer reading device / software, with which the numbers are simply be keyed in and instantly, the account is correlated with previous use and

current cost basis with a receipt printed for the driver to cover the cost of its previous use and the surcharge for battery exchange, at the point of exchange mentioned, this being stored in a internationally connected global cloud database for management of national logistics, as well as client based account management and administration metadata or other analytical tools, integrated into the database and communication system, connected to the point of exchange participants, which will enable many analytical tools to produce cost saving benefits, statistical analysis and other information useful to upgrade, enhance and extend the value and effectiveness of this new revolutionary technology and system.

- In addition, the point of exchange participants will take all of the accumulated used fuel cells to a centralized recycling facility center, which will recycle and exchange new battery units to the participating point of exchange entity, creating a seamless ecosystem and closed loop life cycle, starting from the vehicle manufacturer who installs the initial battery, to the point of exchange participants, to exchange and send them for recycling across new fuel cell batteries for redistribution into the logistic chain, all giving the driver, the car manufacturers, and the national distribution structure a solid base for continuity and viability.

The major cost reduction factor in addition to the reduction of per unit automobile manufacturing cost lays the fact that **this new revolutionary technology does not need a national charging system or a national charging infrastructure** which is very expensive cumbersome and sometimes unreliable with this business model and technology this entire cost heavy cumbersome and technologically crude business model is exchanged for a vibrant new streamline cost-effective secure and effective system to maintain a national electric vehicle industry and commercial support metrics.

The company intends to develop the first commercial relationships between manufacturers and the company, as well as to establish the first recycling and manufacturing facility for the new battery technology during the 2nd quarter of 2021, whereby an initial buildout and establishment of all features related to the launch of this new revolutionary technology should be completed in its 1st phase, within the initial 18 months.

While the market value of the solar industry of opportunities in current projects as listed above, in addition to the new groundbreaking technology associated with the aluminum air fuel cell battery owned by ENKS, is comprised of market values exceeding many billions of dollars for the purposes of the companies projections we use a market dominance figure of 5-15% which is not quantified by professional valuation at the time of this writing, but such valuation study has been contracted to professional valuation experts and a comprehensive market value analysis will be produced in a short period of time estimating the minimum discounted market value of each segment as previously discussed as well as the following additional market segments for which the company has acquired Intellectual property rights product services and other commercial value.

The included graphic representations/images, show the **point of exchange** infrastructure the battery manufacturing and recycling facility concept as well as other related design features mentioned herein may be found in this document, while the readers should take notice of risky disclosures and legal disclaimers for forward-looking statements previously mentioned herein as to the fact that none of this information should be used in any decision to buy or sell shares in this or any other company stock involved in new technologies or otherwise, taking only professional advice from independent experts, before making any decision and further taking notice that the investment in new technologies can result in gain as well as the partial or total loss of any investment, in this or any other company involved in new technologies and product or service categories, as well as EPC solar market which is vulnerable to global economic changes and other mediating elements such as political, exchange rate, or other risk metric categories.

More Detailed Discussion:

NEW DISRUPTIVE FUEL CELL (BATTERY) TECHNOLOGY PATENTED UNDER OWNERSHIP ENKS (ENERKON SOLAR INTERNATIONAL, INC), OTC ENKS.

New disruptive fuel cell technology in the form of aluminum air fuel cell delivering more power and longevity with no toxicity or explosive danger such as found in lithium ion/ cobalt/ other battery and fuel sale technology available today.

The unique technology advantage of aluminum fuel sales (battery) is primarily safety, longevity and weight (30% less weight than conventional battery) and is non toxic property and inability to explode or corrode.

As depicted and the patent diagram here the addition of nano particular size of silver substrate into the fuel cell eliminates competitor version failing/ gel buildup which greatly reduce the longevity and power output, our technology alleviate this troublesome side effect found in the reaction between aluminum and specialized electrolytes and in particular the electrolyte use in this new disruptive technology, is nontoxic to the environment and absolutely safe from any fire or explosion under any circumstances.

The aluminum fuel cell battery technology owned by ENKS is a real game changer for the industry of electric vehicles, electric aircraft and other uses which require long life, high output fuel cell battery driven energy.

Other aspects related to this new disruptive technology lay in the fact of the unique distribution and use model has been developed to enable the most users friendly and hazard free fuel cell exchange and recycling.

The aluminum fuel cell battery owned by ENKS is 100% recyclable and it's plug and play fuel cell battery. This compartmentalized fuel cell battery can be interchange with A new fuel cell battery upon discharge within only a few minutes during a normal stop at any of the nation's participating franchise, gas stations or roadside shops.

The point of exchange (POI) business model and logistic system prides of distributed agreement with franchise gas stations and roadside services shops throughout the country, in the nations adopting the new technology wherein the automobile in this particular explanation is given an exchange of fuel cell on the spot while making other maintenance or simply buying a soda in the shop whereby the fuel cell will be exchange and the calculation will be made of the auto meter reading of the vehicle and this will be keyed in at a POE device or software which connects to a global interconnected cloud based real time database which calculates the use of energy and bills the customer on a per kilometer basis according to an automatic formula which is adjusted to at or below market cost for normal electric vehicles usage per kilometer of travel, this being different from one country or region to another, but in all cases the cost basis is at or below the market national average

The collection and distribution of aluminum fuel cell batteries by the point of exchange participating franchise shops and stations is a unique and forward looking concept into the future of electric vehicles logistics and maintenance, in addition, the collection of discharge of aluminum fuel cell batteries are then accumulated and send to a centralized recycling center within which is also a primarily production factory for additional as well as recycling aluminum fuel cell batteries 1 whereby the national system is replenished in real time and ecologically friendly life cycle with a low cost basis and highly effective output for the benefit of the environment as well as the consumers and point of sale or exchange participants, who benefit by collecting small royalty per kilometer/hour on each exchange battery, giving them the incentive to participate in the program as well as the national marketing and other related market support features which gives them considerable incentive to participate over the long term, similar to franchises taking western union, PayPal, or other similar platform systems in their shops to add extra revenues, just as an example.

The aluminum fuel cell battery is an absolutely revolutionary concept, it's not a new concept as the technology has been researched in Asia, in Europe and other regions for many years, while the current version of the aluminum fuel cell battery owned by ENKS, became revolutionary and feasible for market release once the problem of oxidizing filing /gel build up at membrane or terminal point was solved and other technological issues where mediated.

Consequently, the aluminum fuel cell battery is being developed for a national launch in the USA and other countries, based upon market and participant's response as well as the reaction of the financial community and the electric vehicle industry stakeholders and governmental regulatory authorities, as well as other important entities participating in this absolutely revolutionary project.

It is expected that during the 4th quarter 2020, initial prototypes will be fielded in the on the road vehicle to display the viability longevity, cost reduction and other positive features of this revolutionary new disruptive technology.

Thereafter, it is expected during the mid-2021 or before, the 1st aluminum cell battery factory will be established preferably in partnership with a major electric vehicle manufacturer, this is assumed due to the fact that the ENKS owned aluminum fuel cell battery is more than 38% cheaper than current battery's technologies including newly released technologies comprised of cobalt and other toxic substrates. This gives the vehicle manufacturers a huge incentive to switch over to ENKS aluminum fuel cell battery technology in order to save on per unit cost in the vehicle manufacturing process, as well as to participate on down line logistics and royalty revenue streams and other profit centers associated with the aluminum fuel cell battery ecosystem.

Lastly, it is our goal that by or before the next year 4th quarter the ENKS owned aluminum fuel cell battery will be the new battery of choice for electric vehicle manufacturing in addition to small aircrafts and other types of vehicles or equipment which need long running, cost effective, high output energy driven by ecologically friendly and effective disruptive technology which is the aluminum fuel cell battery owned by ENKS.

We invite interested industry participants, national stakeholders, governmental regulatory authorities, financial community entities and related point of exchange franchise candidates to contact us for more information and to enhance and develop our already growing partnerships within the electricity driven vehicles both on land and air and sea, as well as other devices and equipment requiring the use of safe long term output fuel cell/battery's systems.

In conclusion, once the success of the foregoing aspirations have been achieved , the company intends to expand the use of the aluminum air battery owned by ENKS to include off peak time solar utility scale, solar energy plants backup battery's systems, as well as wind farm off peak backup storage facilities and other similar renewable energy backup support requirements , in addition to use in certain remote military, medical or other facility which requires similar safe effective fuel cell battery technology over the long term.

The ENKS Covid-Shield PI™ (passive immunity) combination drug therapy prophylactic protective regime drug treatment trademark and patented by ENKS

ENKS Covid-Shield PI™ a significant potential global market value exceeding many billions of US dollars, once clinical trials and/or regulatory approval/exemptions and/or licensing may be approved in various jurisdictions around the world the company is positive that considerable progress will be made during the next 10 to 18 months as to the implementation and delivery of this unique holistic protective drug therapy, to the commercial markets.

Covid-Shield PI™ serves as a passive immunity stimulator, using the pathways COVID-19 requires to enter human cells, by blocking these receptor sites and thereby prohibiting the infection and proliferation of the COVID-19 pathogen throughout the human body to a very high degree (estimated at least 85+% efficacy in current studies so far).

The viability of using off label, FDA approved active ingredients, in a novel and unique combined way, together with auxiliary compound, is an absolutely effective methodology in protective care drug therapy regime, and while Covid-Shield PI™ is not a vaccine, it does produce a vaccine type effect in the form of passive immunity though the blocking of required receptor sites in particular, ACE 2 and others, throughout the body during the course of treatment which has been studied and proven to be relatively safe over long periods of consumption for most people in particularly those most susceptible in the critical demographics of elderly, infirm, children and similar essential worker categories

The Covid-Shield PI™ combination drug therapy concept is unique and the intellectual property rights assigned to this product category is considerably valued in our current present day circumstances and while the market could be many billions of dollars the international financial and economic situation or other regulatory or administrative issues could preclude this value to materialize and therefore the investment into ENKS or any other company utilizing new technologies as a basis for market value forecast and estimates must realize that while there can be a significant gain, there can also be a complete and total loss of investment and none of this information should be used to make any decision on purchasing or selling shares of this or any other companies involved in new technologies and products.

The Covid-Shield PI™ multidrug prophylactic therapy product, is intended to be marketed worldwide to the most vulnerable demographic population once the previous studies and approvals by the FDA have been obtained.

The active ingredients used in their **on-label use** form, have produced a very little to no side effects or interaction between these combined active ingredients while the **off label use** of these active components, combined together, **have not been approved by the FDA** nor have long-term combined therapy studies taken place for this specific combination matrix, as utilized by the Covid-Shield PI™ drug regime,

However, the company remains confident that regulatory approval, or exemptions, will be granted soon due to the current global urgency and the previous data already reviewed by the FDA, for on label use simply taking an approach of regulatory review and approval, based on off label use basis, with **the main focus being interaction and side effects, which the company believes are minimal based on current studies and scientific results.**

More Detailed Discussion:

Technical discussion on Covid-Shield PI (Passive Immunity) Multi drug combination, prophylactic therapy

The unique combination drug therapy which is comprised of multiple FDA approved on-label Drugs currently in circulation around the world for decades, with a long histories of efficacy and safety, do in fact produce a synergistic effect, (when combined together in the presence of additional ingredients which are equally safe and effective according to long historical analysis), produce a form of “**passive immunity**” for the person consuming a medium or long term dose regime (4-8 months during flu or pandemic wave season) of Covid-Shield PI, Combination Prophylactic Drug Therapy, (creating a Passive Immunity to Novel Coronavirus Covid19).

The unique combination drug therapy has been designed based on scientific evidence which has revealed the methodology by which the novel SARS coronavirus (COVID-19) infects human cells, the primary pathway utilized by this novel coronavirus pandemic pathogen is through a ACE - 2 receptor binding pathway, as well as other mediators, and once infecting human cells, the pathogen replicate and proliferates to the point of triggering a significant immune reaction in the infected host/person.

The problem with this novel SARS coronavirus (COVID-19), is that it does not behave in all respects as a common virus or, a known pathogen, due to the fact that it utilizes a unique pathway for infection, while creating potential fatal consequences and multiple negative pathologies, by virtue of the significant provocation of the human Immune system complex, to such a degree, that it has manifested in many different forms across many different demographic categories (elderly, youth, children, and others, of all ethnicities), these potentially fatal side effects of COVID-19 infection include, but are not limited to, the fatal effects of “cytokine storm”, which once triggered can quickly cause death in an infected person, due to the violent inflammatory reaction associated with “cytokine storm”.

The unfortunate consequences of the above side effects, related to significant provocation of the immune system response are problematic, due to the fact that they present themselves in multiple ways, confusing common clinical diagnoses and determinations, confusing the best treatment options needed for deployment, in order to save infected patients.

An example of this, may be that in many cases of intubation and ventilation, patients on ventilators have proven have a marked increase of morbidity (death), due to the fact that the oxygen perfusion, the transfer of oxygen between the lung tissue and the bloodstream, is not being prevented due to a mechanical defect, or only a mucosal obstruction, but primarily due to a mass inflammatory response, within the minute structures of the lung tissue itself and in many cases if not all, there is at least some thrombosis present in capillary systems, and other thrombotic related events, diffuse across the body, affecting not only the lungs, but in many cases, the heart, brain, kidneys, and other organs as well.

This has become a common symbolic pathology, of this novel coronavirus infection, and therefore the need for prevention has increased greatly, due to the fact that it is a very dangerous pathogen, and once a person has been infected, is very challenging to eradicate, control, and prevent the death of the infected patients, due to the diverse damage inflicted by this pathogen on some, or most, of the vulnerable demographic populations.

The treatment in an ICU setting for COVID-19 patients have evolved considerably, due to the real time emergence of new information and studies yielding more clarity towards the actual function and proliferation of COVID-19 we find another example, of which is that only several known drugs, such as Actemra, or interferon alpha-2b, (one being an inflammation mediator, and the other being more - specific for interleukin 6 receptor site binding), both contributing to the arrest and/or reversal, or at least, minimization of cytokine storm damage when administered early and under controlled monitoring.

This has been a very positive development as all of the Covid shield PI components, (active ingredients) have also shown significant promise, in suppressing the severity of moderately ill patients, without the use of Actemra or interferon alpha-2b in clinical a setting when administered after infection and more importantly, it has s clear Passive Immunity against the Covid 19 Pathogen in Patients who have not yet been exposed or infected.

Covid-Shield PI, can also be used combination with Actemra or interferon alpha-2b treatment protocol, to reduce the severe infections and inflammation response and potential morbidity, as well as being used as a prophylactic, preventing the infection in the first place, through the presentation of passive immunity, produced by the effects of Covid shield PI, receptor blocking properties, and other inflammation mediators, immune system stabilizers, and metabolic support components, all being a part of the full spectrum approach, of the combined drug therapy treatment, which is Covid-Shield PI (Passive Immunity).

The company hopes that Covid shield PI, will become a benchmark prophylactic treatment for all vulnerable demographics and “essential worker” categories, as well as others, with may wish to participate in a safe and effective drug regime, producing a prophylactic passive immunity and while not being a vaccine, it may be the next best thing, producing a protective barrier between the individual and the viral pathogen COVID-19 using a new methodology – acting in a very similar role of a classic Vaccine.

The efficacy in-vitro and in-vivo study, show reproducible results of 85% to 90+% efficiency in the complete blocking and/or suppression of infection by COVID-19 in susceptible populations, and this percentage is acceptable, due to the fact that it actually exceeds the percentile ratio, and effectiveness as claimed by seasonal flu vaccine and other related vaccines, used over the previous decade, by considerable degree.

For example, the flu vaccine/flu shot, has an effectiveness of not more than 65% at best and 40% at its worst, based on decades, of statistical Data.

Therefore, Covid shield PI, has shown so far to be a greatly more effective in preventing infection or mediating it severity, than vaccine therapy itself per se, using what may even be a safer pathway, blocking the ability of COVID-19 to infect humans cells, as well as mediating and limiting the effects of such infections, if it should occur, thereby protecting the patient or person from a potentially morbid effects and even death associated with this virulent strain of this novel SARS coronavirus (COVID-19).

Potential Risk Factors Examined:

The only scientific argument for concern, has been the concept of “potential interaction” (negative side effects), between the active ingredients of Covid - Shield PI, which is a combination drug therapy, prophylactic passive immunity regime.

The results of this review has proven that the active components of Covid-Shield PI, have little or no interactivity, or contraindications, between the respective combined active ingredients, (all of which are FDA approved for their own label use, the approved for off label use in combined drug therapy presentations such as Covid shield PI has not yet been FDA approved while we are confident it will be in the very near future due to the face that the Multi Drug Combination has decades of historical statistics on safety and interactions as well as contraindications and / or side effects- due to the face that all of the active ingredients of Covid- Shield PI have long been approved by the FDA for On-label use).

The effectiveness is clear as is the lack of significant contraindications or side effects or interactions between any of the combined components, this being a very positive outcome as to safety and effectiveness and gives the company a hopeful and positive view, as to regulatory approval and/or exemptions from regulatory approval, for off label use, or other exemptions, this as well as the urgent regulatory review atmosphere, created by the violent nature of the current global pandemic, the COVID-19 plague which has presented the global health community and the global population with a stark choice to balance, administrative and long term trials and studies, between a balanced short-term, scientific review, filtering out any dangerous therapy candidate, for the protection of the population, this balance must be struck in a pragmatic manner, using only scientific data and comparative analysis, as the tools to decide whether an alternate methodology, or another treatment regime, is in fact safe enough to release for mass consumption, across the most vulnerable demographic categories.

We believe that Covid shield PI, is one of those drugs and one of those treatment regimens which fall under the category of having a permissible level of safety and efficacy, which the global population deserves to have available, to protect them and their families from potential infection by this virulent strain of novel coronavirus COVID-19 pathogen.

In the coming weeks, the company intends to aggressively pursue, together with our scientific and medical expert partners and associates, regulatory and administrative authorities in various countries around the world, in an effort to increase and enhance human trial participation using Covid shield PI, with the goal being to provide this treatment option to the broadest demographic populations who need it the most as soon as possible with the least regulatory/administrative delays, while in keeping with the highest level of safety and efficacy standards, utilizing scientific data and actual results as a guide, in addition to historical comparable data, which significantly support our projected opinion, that Covid shield PI is in fact a new and potentially revolutionary treatment to protect against the infection by COVID-19 as well a legitimate and effective treatment to mediate and suppress the potential deadly effects of the pathogen in the case of a person who has already been infected and therefore, we feel that we are obligated to do our best, in bringing forward in a safe and effective legal and balanced manner, the Covid -Shield PI combination drug therapy as a prophylactic passive immunity drug regime product, and in addition we will be adding other support products, to the company's sectors targets which would entail other types of mediating products, such as specialized saline nasal spray, currently approved by the FDA for over the counter use, as well as specially prepared mouthwash and gargle preparations, also currently approved for over the counter use, all these to be used in combination with the Covid shield PI combination drug therapy, over periods of high risk of infections throughout the year (between 4 to 8 months depending on seasonal cycles for coronavirus infections, including this particular SARS novel coronavirus COVID-19 pathogen).

In conclusion, we should publicize an expanded white paper and technical review for public discussion and peer review, during the coming weeks, while enhancing our drive towards market access, to the prescribing medical community and consumers who need to be protected from the SARS novel coronavirus known as "COVID-19".

ENKS - Albayraklar, intellectual property rights and new product acquisition for police, law-enforcement military and defense use categories summarized below:

ENKS has acquired 20% interest and Albayraklar defense system unit owned by the international conglomerate Albayrak Group a multibillion revenue company established in 1958 with first right of refusal to acquire the remaining 80% shareholding.

The patented intellectual property rights and products are comprised of WATTOZZ/(stingray) new handheld electric stun gun weapon system for police, defense and law enforcement support, as well as military police and other security personnel worldwide, as a viable replacement to the primary competitor called **Taser**, produced by Axion Corporation in the USA.

The WATTOZZ/stingray handheld electric stud gun is a revolutionary new technology once again which is patented and field tested producing excellent results as far as effective, safety, capability and viability, far outpacing the same as similar metrics associated with its primary competitor taser as produced by Axion company in the United States previously mentioned, mainly due to the fact that this particular new disruptive technology does not require wires or any physical connection to the target which is not the case with taser which requires cumbersome wires to be deployed with dangerous barbs which cannot be effectively targeted and have caused serious injury and in many cases deaths due to cardiac arrest or other cardiac damage as a further result of the inability to shut off, or sense cardiac danger or arrest in targets before it's too late.

The WATTOZZ/stingray hand held electronic stun gun has no wires, operates completely over radio frequency and deploys a autonomous dart to the target with a range far exceeding that of the main competitor taser, and having multiple cartridges enabling multiple targets to be engage and controlled at the same time both manually as well as automatically, artificial intelligence and on board circuitry sense and prevents potential cardiac arrest or damage to targets, in the case as if such situation may arise allowing the officer to intervene with other restrain system and administer emergency medical care as well.

In addition to the foregoing the WATTOZZ/stingray hand held electronic stun gun utilizes an onboard camera for evidence collection and use and mitigating litigation as well as enforcing conviction in the case of law-enforcement arrest and activities surrounding the use of this particular electronic weapon system for police and law-enforcement support.

A laser targeting system is also deployed on board the device to gain high target acquisition and placement specificity, when the cartridge is discharged from the device to the intended target, which also utilizes kinetic energy versus the combustion of any substrate or compressed air as in the case of the primary competitor taser, which in many cases fail and cause great danger to the officer who has now become vulnerable and defenseless and may have to actually engage his lethal weapons, to defense himself, escalating the situation to a potentially negative outcome.

The positive features of this new police/law-enforcement support, non-lethal weapon system is a groundbreaking reality for officers or security practitioners, military police and others worldwide and the company has already achieved more than 300 signed distributors throughout the world and several hundred thousand pre-ordered units at present time.

The company further enjoys a Baker-Tilly valuation report and establishing the market value for this device more than 1.1 billion dollars USD for which the company has written down for the purposes of balance sheet forecasting by more than 70% in order to maintain a feasible risk analysis and assume the value target matrix for the company's revenue forecast and operational analysis/projection.

In addition to the above WATTOZZ/stingray hand held electronic stun gun weapon system for law enforcement and security industry functionaries, the company has further acquired additional patents and products in the form of a new, armed, **unmanned aerial vehicle** (UAV/drone) armed with a rotary torrent capable of firing without destabilization, using a new technology for stability and target accuracy onboard the vehicle, prototypes of which are being currently produced now and due to the highly regulated nature of this particular product category being supervised and regulated pursuant to ITAR and related regulations as well as some international treaties or rules shall require the company to lobby regulatory authorities for the requisite license, permission and/ or exemption categories in order to sell this technology to government only clients in said categories of defense or critical infrastructure protection use categories, such as anti-drones, counterterrorism, parameter defense and surveillance

The ENKS/Albayraklar partnership, has resulted in further acquisition and first right of refusal access, to revolutionary new patented product category of **underwater drone technology** in the shape of a manta ray/stingray, using robotics and fluids dynamics as well as other new technology to enabling a device which appears to be a large sea creature, but is actually an armed semi-autonomous underwater drone, utilizing non-RF and non-microwave communication technology but rather **sonar-based communication technology** and artificial intelligence integrated on board computers systems which allows swarms of the underwater devices to communicate with each other and deploy to their targets semi-autonomously and once these devices are deployed, they shut down until the target has assumed to be within range, based on its last location and trajectory, at which time the units turn themselves back on and move to engage their intended target, attaching themselves to the bottom or sides of the marine target vehicle, detonating themselves where they were previously ordered to do so in the case of a military engagement for defensive purposes are otherwise accordance with the international law and rules and regulations which pertain to the use of such a weapon systems and technologies and again this being a controversial and highly regulated technology and product matrix, ITAR and other related regulatory bodies both domestically and internationally must first be consulted and approval/ permissions, licensing exemptions, or other category latitude must be first derived before, engaging sales of such technology and devices in the commerce, in keeping the domestic laws and regulations which are pertain to such technology categories and product technology and product categories for defensive purposes and particular maritime defense.

While the market value for such a system and platform is considerably large and relatively unknown as to its actual scope, the company does estimate that multi-billion dollar sales in the future could be possible with the respective support and regulatory approval, governmental permissions being granted as well as the markets acceptance of this new revolutionary technology which will mostly **replace** the non-autonomous underwater drone systems which use radio frequency microwave transmissions and other frequency communication tools, to a frequency base communication tool which can be easily jammed or mediated, by the targets defenses, relegating the weapon system useless for the most part, in many circumstances therefore the difference between this classes of underwater drone weapon system or remotely controlled torpedo lays in the fact of physical appearance, communication emissions and related foot print and signatures which makes the device very difficult to detect and furthermore quite difficult to defend against, due to their semi-autonomous nature and construction using both shielding and non-RF communication methodology (sonar and related new technology for inter communication between swarm weapon system network communications).

Consequently, the company is excited about this new technology for which it has acquired in partnership with Albayraklar defense unit and respective wholly owned corporate division called WATTOZZ holding Inc., for which ENKS holds a 51% ownership and shareholding will Albayraklar holding a 49% shareholding ratio respectively therewith.

The same risk category disclaimers mentioned above, apply to this category as well as including the fact that Investors should not use any of this information to base decisions upon purchasing or selling any shares in this or any other companies utilizing new technologies or similar system without first consulting independent third-party expert advisors and taking note of the fact that the valuations assumed herein and may be reduced to zero depending upon regulatory rejection or lack of approval or political or market matrix changing due to economic or Geo political reasons affecting the ability to sell into commerce this new revolutionary technology and products weapon system platform/weapons.

ENKS (Enerkon Solar International Inc,) OTC, intends to acquire additional intellectual property rights, as well as new revolutionary product and services for deployment into global commerce as its primary business model going forward, focusing on the course of least resistance and sectors shown to be the most favorable, modifying company/s focus as the environment may change, in order to produce the greatest shareholder value, corporate and administrative stability and market confidence, as well as the long term viability of the company as an ongoing concern.

In addition to the graphic representations, pictures and images included in this presentation material, the company include some financial projections and pro forma analysis educational purposes only.

Professional and expert third-party opinions should be taken to review any of this information and none of this information should be used otherwise to form any decision to purchase or sale shares or make investments in this or any other companies involved in the acquisition of new technologies and products as well as the current field of solar renewable energy and other commercial activities mentioned herein.

